Patrick Loofbourrow

San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Cooley advised Holmusk on its $45 million Series B financing. Partners Ferish Patel and Patrick Loofbourrow led the Cooley team advising Holmusk, a global behavioral health and data analytics company developing a technology designed to support treatment of mental health and chronic diseases.

Cooley advised Carousell Group, a classified ads marketplace in Greater Southeast Asia, on its $100 million investment. Partners Patrick Loofbourrow and Matthew Bartus led the Cooley team advising Carousell.

Cooley advised Japanese company Paidy, a two-sided payments platform and provider of buy now, pay later (BNPL) solutions, on its agreement to sell to PayPal for approximately $2.7 billion in cash. Lawyers Rama Padmanabhan, Patrick Loofbourrow, Rowook Park, Andrew Harline and Vivian Tsai led the US- and Asia-based Cooley team advising Paidy on the transaction, which highlights Cooley’s strong capability for executing complex, globally handled deals.

Cooley advised Cytek Biosciences on its $200 million initial public offering of 14,564,635 shares of common stock. Cytek Biosciences, whose securities now trade on the Nasdaq Global Select Market under the symbol CTKB, is a leading cell analysis solutions company. Partners Gordon Ho, Patrick Loofbourrow and John McKenna led the Cooley team.